Business Description: Brookwood Pharmaceuticals, Inc. is a drug delivery company that applies its patented and proprietary technologies to design, formulate, and manufacture improved pharmaceutical products. The company holds more than 20 drug-delivery patents, and has expertise and facilities for feasibility studies, formulation and product analysis, scale up, clinical lot preparation, and production of final dosage forms. The clinical applications of Brookwood technologies are diverse with current partnered programs covering metabolic, cancer, orthopedic, drug/alcohol addiction, psychosis, ocular diseases and sun-induced conditions. Brookwood Pharmaceuticals, a product-focused company, has a wide-range of delivery technologies particularly for long-acting parenterals such as injectable microparticles and injectable solid implants to deliver small molecules, peptides, proteins, nucleic acids, and other biological macromolecules. Partnered programs range from feasibility studies, product development and optimization, process scale up, clinical trial and manufacturing of drug-delivery formulations and biomaterials.One contract manufacturing program in Phase III.
History: Brookwood formed in January 2005 by a spin out of the Pharmaceutical Formulations Group at Southern Research Institute. As part of the not-for-profit Southern Research, the prime focus of that group over a 30-year history was as a technology center of excellence for controlled release, drug delivery, and medical applications of biodegradable polymers. This group played an integral role in many technologies and products, including the first commercial injectable microsphere drug products in Europe and the US, and the Atrisorb technology of Atrix (now QLT). More recently this group had in parallel developed its own proprietary technologies and manufacturing capabilities, and with these accomplishments was poised to become a profitable, stand-alone venture. The management and technology team from the Pharmaceutical Formulations Group at Southern Research moved to form Brookwood. This group was supplemented with a seasoned management and technical team with experience from other drug delivery companies. In 2005 Brookwood announced the acquisition of Alkermes external polymer business, which was incorporated as a wholly owned subsidiary, Lakeshore Biomaterials. Brookwood has current revenues from three sources: contract R&D funding from pharmaceutical and biotech partners, contract clinical trial manufacturing, and sales of biodegradable polymers. All three sources have potential for growth. Long-term revenue growth will be based on milestones and royalty income from licensed Brookwood technologies as partnered products receive regulatory approval and market introduction; on contract manufacturing of those products; and on licensing of proprietary products.
Market and Customers: Brookwood and its Lakeshore Biomaterials subsidiary have over 40 active customers. Six of Brookwood’s drug-delivery programs are with the top fifty worldwide pharmaceutical companies and two with top 10 medical device companies. Some highlights of current efforts in conjunction with pharmaceutical partners are:
Two partnered products in Phase II.
One contract manufacturing product in Phase I.
A number of other partnered products at preclinical stage, three of which are scheduled to enter clinical stage by 1Q07.
Last Updated: 11-20-2006